Month: August 2025

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical-stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and … Read more

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical-stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and … Read more

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical-stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and … Read more

ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) — Countdown For A Cure, a foundation dedicated to accelerating mitochondrial research and medicine, today announced a $350,000 grant to Minovia Therapeutics Ltd., a clinical-stage company pioneering mitochondrial transplantation technologies. The funding will support Minovia’s research proposal to develop novel mitochondrial blood-based biomarkers that quantify mitochondrial content, quality, and … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline. So … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of iRobot Corporation (NASDAQ: IRBT) between January 29, 2024 and March 11, 2025, both dates inclusive (the “Class Period”), of the important September 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased iRobot … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Biohaven Ltd. (NYSE: BHVN) between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”), of the important September 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Biohaven … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Centene … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the “Western Asset US Core Bond Fund” mutual fund classes – Class I (ticker: “WATFX”), Class A (ticker: “WABAX”), Class C (ticker: “WABCX”), Class FI (ticker: “WAPIX”), Class IS (ticker: “WACSX”), and Class R (ticker: … Read more

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the “Class Period”), of the important September 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased … Read more

Funding supports next-generation AI agent development and proprietary Intellectual Property, focused initially on pharmaceutical drug-repurposing Initial clients reporting commercial success, revolutionizing indication selection of lead programs Early commercial success and key partnerships signal strong market traction and scalability potential into multiple commercial verticals WILMINGTON, Del., Aug. 27, 2025 (GLOBE NEWSWIRE) — Sarborg Limited (“Sarborg” or … Read more